Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.42 |
| ▸ | TNF | P01375 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313102 | 0.81 | CCR1 (0.42) | HDAC3HDAC1HDAC6 | |
| SCHEMBL23988661 | 0.80 | F12 (0.48) | EGFRMAPTMET | |
| SCHEMBL30727448 | 0.80 | TNF (0.46) | TNF | |
| SCHEMBL24151604 | 0.80 | PLAU (0.47) | EGFRTNFHDAC3HDAC1HDAC6 | |
| SCHEMBL16455340 | 0.80 | CTDSP1 (0.38) | EGFRTNFMAPT | |
| SCHEMBL27051340 | 0.80 | TNF (0.46) | TNF | |
| SCHEMBL2671305 | 0.75 | PLAU (0.55) | HDAC3HDAC1HDAC6MAPT | |
| SCHEMBL4479184 | 0.75 | CYP2A6 (0.55) | EGFRMAPT | |
| SCHEMBL16455342 | 0.74 | MAPT (0.43) | EGFRMAPT | |
| SCHEMBL27692880 | 0.73 | LATS1 (0.47) | TNFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423196-A1 | 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof | Rexahn Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034829-B2 | e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. | REXAHN PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | FANCD2, NRAS, CCND2 | EGFR 879/4885TNF 4768/4885HDAC3 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.